Sharescart Research Club logo ×
Screener Research Unlisted Startup Funding New IPO New

  • Home
  • /
  • Astec Lifesciences
Join Channel
Consolidated Standalone

Astec Lifesciences

₹1192.8 1.3 | 0.1%

Market Cap ₹2339 Cr.

Stock P/E -49.8

P/B 6.3

Current Price ₹1192.8

Book Value ₹ 188.3

Face Value 10

52W High ₹1541.7

Dividend Yield 0.13%

52W Low ₹ 826.2

Edit Ratio

Astec Lifesciences Research see more...

Overview Inc. Year: 1994Industry: Pesticides & Agrochemicals

Astec LifeSciences Ltd is an totally India-based holding enterprise. The Company is engaged in agro chemicals, consisting of fungicides and herbicides enterprise. It manufactures a number of agrochemical active ingredients and pharmaceutical intermediates. The Company's merchandise provides agrochemicals, including tebuconazole, propiconazole, hexaconazole, difenoconazole, epoxiconazole, cyproconazole, flutriafol, tricyclazole, metalaxyl and lambda cyhalothrin, and intermediates, inclusive of 2, 4-dichloroacetophenone, 2-chloro-4-fluoro acetophenone, 4-methyl phthalic anhydride and thio bis-4-chloro thymol. The Company's multi-purpose production centres are placed in Dombivli, which is over 50 km from Mumbai, and Mahad, which is over 180km from Mumbai. Its multi-motive plants are primarily based on 3,000 liters to 20,000 liters glasslined and stainless steel reactors. In addition, the Company has undertaken some of custom synthesis initiatives for clients in Europe, Japan and the USA.

Read More..

Astec Lifesciences Share Price

New

₹ | |

Volume
Price

Quarterly Price

Quarterly Monthly
Show Value Show %

Peer Comparison

Astec Lifesciences Quarterly Results

#(Fig in Cr.) Dec 2021 Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024
Net Sales 173 272 184 200 117 127 143 111 51 154
Other Income 2 7 3 4 4 3 2 1 1 2
Total Income 175 279 187 204 121 130 145 112 52 156
Total Expenditure 130 207 159 166 105 122 140 114 69 141
Operating Profit 45 72 28 37 16 8 5 -2 -17 15
Interest 3 3 4 5 6 6 6 6 6 7
Depreciation 9 11 9 8 9 8 9 9 9 9
Exceptional Income / Expenses 0 0 0 0 0 0 0 0 0 0
Profit Before Tax 33 58 15 25 1 -6 -11 -18 -32 -1
Provision for Tax 8 15 4 6 0 -1 -3 -4 -8 0
Profit After Tax 25 43 11 18 1 -5 -8 -13 -24 -1
Adjustments -0 -0 -0 -0 -0 -0 -0 -0 -0 -0
Profit After Adjustments 25 43 11 18 1 -5 -8 -13 -24 -1
Adjusted Earnings Per Share 12.6 22 5.8 9.3 0.4 -2.5 -4.2 -6.8 -12.4 -0.5

Astec Lifesciences Profit & Loss

#(Fig in Cr.) Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 TTM
Net Sales 175 207 267 247 299 368 431 523 555 677 628 459
Other Income 1 0 1 7 3 8 11 12 8 10 13 6
Total Income 176 207 268 254 302 376 442 535 563 687 641 465
Total Expenditure 148 172 213 215 236 299 354 437 443 522 552 464
Operating Profit 28 36 55 39 65 77 88 97 119 165 89 1
Interest 7 9 13 13 12 11 12 13 5 9 21 25
Depreciation 12 15 13 10 14 15 19 23 26 34 34 36
Exceptional Income / Expenses 0 -1 -17 -3 -11 4 0 0 0 0 0 0
Profit Before Tax 9 11 13 12 29 56 56 61 89 121 35 -62
Provision for Tax 3 2 -2 7 10 21 20 14 24 31 9 -15
Profit After Tax 6 9 15 5 19 35 36 48 65 90 26 -46
Adjustments 0 0 -0 -0 -0 -0 -0 -0 -0 -0 -0 0
Profit After Adjustments 6 9 15 5 19 35 36 48 65 90 26 -46
Adjusted Earnings Per Share 3.3 4.7 7.6 2.6 9.8 17.9 18.3 24.3 33.2 45.9 13 -23.9

Growth Rates

# 1 Year 3 Year 5 Year 10 Year
Sales CAGR -7% 6% 11% 14%
Operating Profit CAGR -46% -3% 3% 12%
PAT CAGR -71% -18% -6% 16%
# 1 Year 3 Year 5 Year 10 Year
Share Price CAGR -11% 1% 22% 41%
ROE Average 6% 18% 19% 15%
ROCE Average 8% 17% 19% 16%

Astec Lifesciences Balance Sheet

#(Fig in Cr.) Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Shareholder's Funds 106 113 135 118 138 170 202 247 309 396 419
Minority's Interest 0 0 0 0 0 0 0 0 0 0 0
Borrowings 21 18 13 8 0 0 0 0 40 0 11
Other Non-Current Liabilities 31 36 36 -2 1 5 9 6 6 38 23
Total Current Liabilities 102 117 178 203 194 238 249 318 322 491 526
Total Liabilities 261 284 362 328 334 413 461 572 678 925 979
Fixed Assets 121 132 133 95 103 115 167 194 213 340 318
Other Non-Current Assets 22 17 25 42 32 66 46 46 134 70 162
Total Current Assets 119 135 204 191 198 232 248 332 330 516 499
Total Assets 261 284 362 328 334 413 461 572 678 925 979

Astec Lifesciences Cash Flow

#(Fig in Cr.) Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Opening Cash & Cash Equivalents 4 5 1 1 2 3 0 0 0 0 1
Cash Flow from Operating Activities 16 15 7 -13 19 65 15 168 -8 24 75
Cash Flow from Investing Activities -13 -19 -19 -16 -18 -49 -52 -74 -73 -104 -113
Cash Flow from Financing Activities -2 3 12 31 -1 -18 37 -95 81 80 38
Net Cash Inflow / Outflow 1 -1 -0 2 1 -3 -0 0 0 0 -0
Closing Cash & Cash Equivalent 5 4 1 2 3 0 0 0 0 1 0

Astec Lifesciences Ratios

# Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Earnings Per Share (Rs) 3.3 4.68 7.59 2.55 9.8 17.87 18.28 24.28 33.21 45.85 13.04
CEPS(Rs) 9.85 12.64 14.12 7.95 16.84 25.46 28.19 36.13 46.32 63.39 30.22
DPS(Rs) 0.75 1 1.25 0 1.5 1.5 1.5 1.5 1.5 1.5 1.5
Book NAV/Share(Rs) 58.38 61.25 69.56 60.28 70.36 86.42 103.16 125.66 157.63 202.17 213.72
Core EBITDA Margin(%) 13.9 16.08 19.11 12.78 19.91 18.55 17.67 16.21 19.94 22.66 12.08
EBIT Margin(%) 8.33 9.27 8.98 10.22 13.08 17.9 15.78 14.07 16.79 19.15 8.82
Pre Tax Margin(%) 4.48 5.07 4.44 5.03 9.17 15.02 12.92 11.67 15.94 17.82 5.54
PAT Margin (%) 3.04 3.93 5.22 2.05 6.12 9.45 8.27 9.04 11.64 13.22 4.05
Cash Profit Margin (%) 9.15 10.64 9.7 6.26 10.49 13.41 12.74 13.45 16.24 18.27 9.39
ROA(%) 2.4 3.17 4.57 1.47 5.8 9.38 8.18 9.2 10.42 11.21 2.69
ROE(%) 5.83 7.91 11.88 4.01 15.07 22.9 19.31 21.24 23.46 25.5 6.28
ROCE(%) 9.21 10.88 11.96 10.65 16.08 23.75 20.31 20.44 22.29 22.21 7.75
Receivable days 88.78 94.59 99.91 136.14 111.38 115.06 103.32 98.14 113.66 123.7 123.89
Inventory Days 94.9 105.53 95.72 105.79 79.66 70.88 72.27 74.31 74.22 78.67 139.29
Payable days 119.39 125.52 136.3 176.72 126.85 121.9 106.55 143.21 176.37 150.04 166.93
PER(x) 5.12 7.85 19.37 76.38 61.59 32.54 29.47 16.47 30.12 38.22 106.02
Price/Book(x) 0.29 0.6 2.11 3.23 8.58 6.73 5.22 3.18 6.35 8.67 6.47
Dividend Yield(%) 4.44 2.72 0.85 0 0.25 0.26 0.28 0.38 0.15 0.09 0.11
EV/Net Sales(x) 0.56 0.71 1.38 2.03 4.35 3.43 2.85 1.68 3.87 5.49 4.85
EV/Core EBITDA(x) 3.5 4.1 6.68 12.9 19.92 16.37 14.01 9.06 17.95 22.56 34.14
Net Sales Growth(%) 54.88 18.42 28.95 -7.45 20.92 23.07 17.23 21.28 6.17 21.93 -7.15
EBIT Growth(%) 116.73 25.98 24.62 -0.75 62.42 61.97 2.87 8.3 26.88 38.76 -57.24
PAT Growth(%) 363.31 46.59 70.86 -65.73 278.55 82.69 2.08 32.89 36.91 38.13 -71.53
EPS Growth(%) 308.91 41.96 62.2 -66.39 283.78 82.44 2.26 32.84 36.78 38.07 -71.56
Debt/Equity(x) 0.69 0.73 0.69 1.08 0.92 0.74 0.87 0.4 0.61 0.71 0.81
Current Ratio(x) 1.16 1.15 1.15 0.94 1.02 0.97 1 1.04 1.03 1.05 0.95
Quick Ratio(x) 0.66 0.5 0.74 0.59 0.69 0.64 0.63 0.66 0.7 0.67 0.39
Interest Cover(x) 2.16 2.21 1.98 1.97 3.35 6.23 5.52 5.87 19.75 14.37 2.69
Total Debt/Mcap(x) 2.39 1.22 0.33 0.33 0.11 0.11 0.17 0.13 0.1 0.08 0.13

Astec Lifesciences Shareholding Pattern

# Dec 2021 Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024
Promoter 65.19 65.29 65.29 66.77 66.77 66.77 66.76 66.75 66.75 66.75
FII 0.29 0.32 0.48 1.53 2.19 2.28 1.95 1.33 1.28 1.25
DII 12.74 12.56 11.78 9.83 9.56 10.58 10.15 10.16 9.74 7.88
Public 21.78 21.83 22.45 21.87 21.48 20.37 21.14 21.76 22.23 24.11
Others 0 0 0 0 0 0 0 0 0 0
Total 100 100 100 100 100 100 100 100 100 100

Pros

Cons

  • Debtor days have increased from 150.04 to 166.93days.
  • Stock is trading at 6.3 times its book value.
  • The company has delivered a poor profit growth of -5% over past five years.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Astec Lifesciences News

IPO

Companies Open Date Close Date Issue Price Cost of 1 Lot GMP Expected Listing Listing Gain(%) Listing Price Current Price Type Exchange

View more.....

Companies Open Date Close Date Issue Price Cost of 1 Lot GMP Expected Listing Listing Gain(%) Listing Price Current Price Type Exchange

View more.....

Companies Open Date Close Date Issue Price Cost of 1 Lot GMP Expected Listing Listing Gain(%) Listing Price Current Price Type Exchange

View more.....

Companies Open Date Close Date Issue Price Cost of 1 Lot GMP Expected Listing Listing Gain(%) Listing Price Current Price Type Exchange

View more.....

Companies Open Date Close Date Issue Price Cost of 1 Lot GMP Expected Listing Listing Gain(%) Listing Price Current Price Type Exchange

View more.....

You May Also Know About

Unlisted Shares Pre-IPO Shares ESOP Shares Delisted Shares

Please Login!

Click to Login
OR
Get free Account

Error!